BMO Capital Markets Initiates Coverage on Certara (NASDAQ:CERT)

Equities researchers at BMO Capital Markets started coverage on shares of Certara (NASDAQ:CERT) in a note issued to investors on Thursday, MarketBeat.com reports. The firm set a “market perform” rating and a $9.00 price target on the stock. BMO Capital Markets’ price objective points to a potential upside of 8.04% from the stock’s current price.

A number of other research analysts have also recently commented on CERT. Weiss Ratings reissued a “sell (d)” rating on shares of Certara in a report on Wednesday, October 8th. Barclays lowered their target price on shares of Certara from $16.00 to $14.00 and set an “overweight” rating on the stock in a report on Friday, November 7th. UBS Group reduced their price target on shares of Certara from $17.50 to $15.00 and set a “buy” rating on the stock in a report on Thursday, August 7th. Wall Street Zen upgraded shares of Certara from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th. Finally, Craig Hallum began coverage on Certara in a research report on Monday, September 29th. They set a “buy” rating and a $16.00 price objective for the company. Six research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $14.67.

Certara Stock Down 1.0%

CERT opened at $8.33 on Thursday. The stock has a market cap of $1.33 billion, a price-to-earnings ratio of 119.00 and a beta of 1.44. The company has a debt-to-equity ratio of 0.27, a quick ratio of 2.09 and a current ratio of 2.09. The firm’s fifty day moving average is $11.56 and its 200 day moving average is $11.31. Certara has a fifty-two week low of $8.13 and a fifty-two week high of $15.69.

Certara (NASDAQ:CERT) last posted its quarterly earnings results on Thursday, November 6th. The company reported $0.14 EPS for the quarter, beating analysts’ consensus estimates of $0.11 by $0.03. Certara had a return on equity of 5.18% and a net margin of 2.62%.The business had revenue of $104.62 million for the quarter, compared to analysts’ expectations of $104.53 million. During the same period last year, the firm earned $0.13 earnings per share. Certara has set its FY 2025 guidance at 0.450-0.470 EPS. On average, sell-side analysts forecast that Certara will post 0.28 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Leif E. Pedersen sold 51,224 shares of the stock in a transaction dated Tuesday, September 9th. The shares were sold at an average price of $10.92, for a total value of $559,366.08. Following the completion of the transaction, the insider owned 73,979 shares of the company’s stock, valued at approximately $807,850.68. This trade represents a 40.91% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 2.33% of the company’s stock.

Institutional Investors Weigh In On Certara

Several institutional investors have recently modified their holdings of CERT. AdvisorNet Financial Inc bought a new position in shares of Certara during the 2nd quarter valued at approximately $25,000. First Horizon Corp purchased a new position in Certara during the third quarter worth $30,000. Versant Capital Management Inc increased its position in Certara by 66.7% during the third quarter. Versant Capital Management Inc now owns 2,881 shares of the company’s stock valued at $35,000 after acquiring an additional 1,153 shares during the last quarter. Caitong International Asset Management Co. Ltd bought a new stake in shares of Certara in the 1st quarter worth about $31,000. Finally, Osaic Holdings Inc. lifted its holdings in shares of Certara by 50.7% in the 2nd quarter. Osaic Holdings Inc. now owns 3,491 shares of the company’s stock worth $41,000 after acquiring an additional 1,175 shares during the last quarter. 73.96% of the stock is owned by institutional investors.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.